Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Ironwood and AstraZeneca Begin Phase III China Trial for Linaclotide

publication date: Sep 13, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Ironwood Pharma and AstraZeneca began their China Phase III clinical trial of linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C). Last year, the two companies announced a $150 million pact ($25 million upfront; the remainder in sales milestones) to develop the product in China. Although the relationship was described as a joint relationship, AstraZeneca has primary administrative responsibility for China operations. More details....

Stock Symbols: (NSDQ: IRWD) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners